Narrow Results

Agilent Technologies licenses SureFISH to BioDiscovery.

Bionomics acquires US-based cancer stem cell company Eclipse Therapeutics.

AB SCIEX announces Biologics Initiative.

Phylogica licences skin-repair peptide to Le Métier De Beauté for cosmetic market.

Brooks' Single-use REMP tubes support optimization of automated serum and plasma storage

Genetic Technologies announces key managerial appointment Mark Ostrowski to head-up US sales for BREVAGen™.

A Journey Inside the Human Body

Seward Stomacher Enables Clean and Odour Free Sample Preparation for Faecal Transplants.

SCIEX and QPS Holdings Enter Collaboration to Establish the BioBA Solution for Bioanalysis of Biologics.

Singapore Ranks 4th in How Its National Policies Impact Global Biopharma Innovation, ITIF Finds in New Analysis Marking World Health Day.

Bosch Introduces New Generation of Pure Steam Generators and Distillation Units to the Market.

Clearbridge BioMedics Partners with the ICR and The Royal Marsden to Demonstrate Label-free Approach in Isolating Heterogeneous Circulating Tumour Cells (CTCs) and PD-L1 Positive CTCs.

Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease.

(Infographic): About Idiopathic Pulmonary Fibrosis (IPF).

Efficient Light-Harvesting of Plants: Conversation with Professor Alexander Ruban.

Takeda Pharmaceuticals in the Emerging Markets.

Burden of Thrombosis-related Diseases in Asia-Pacific.

GE Healthcare's Cell Culture Media Facility in Singapore.

Waste Management in Singapore: Where Does Our Rubbish Go?

Asia's Medical Technology Start-ups Get New Fast Track to Market via Partnership between Cambridge Consultants and Clearbridge Accelerator

Mitsubishi Electric and Sembcorp Industries to Testbed Novel Ozone Backwashing Energy-Saving Membrane Bioreactor

LEO Pharma Enters Biologics through Strategic Partnership with AstraZeneca

Bayer and X-Chem Expand Drug Discovery Collaboration to Discover Novel Medicines

New Gas Chromatography System Brings Power of Orbitrap GC-MS Technology to Routine Applications

A*STAR and MSD Establish a New Research Collaboration to Advance Peptide Therapeutics

Stem Cells Engineered to Grow Cartilage, Fight Inflammation

AbbVie's First Manufacturing Facility in Asia

The QUATTROR® Dual Mobility Cup: A Technical Revolution in Total Hip Arthroplasty

Merck and MD Anderson Cancer Center Enter Three-Year Strategic Collaboration.

Cervical Cancer: A Preventable Disease.

Consumption of Grilled Meat Linked to Higher Mortality Risk Among Breast Cancer Survivors.

Prostate Cancer Team Cracks Genetic Code to Show Why Inherited Disease Can Turn Lethal.

Social Interaction Can Affect Breast Cancer Outcomes.

One More Piece in the Puzzle of Liver Cancer Identified.

Synpromics Announces a Research Collaboration with GE Healthcare to Extend the Toolbox for Production of Biologics.

Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases.

Asia-Pacific, the rising region for cancer vaccine clinical trials.

Non-small cell lung cancer has largest number of clinical trials in Australia.

Global dermatology pipeline to see shift towards increased usage of biologics.

FDA approves first 0.1 mg auto-injector for life-threatening allergic reactions in infants and small children.

FDA approves first two-drug regimen for certain patients with HIV.

New early-breast cancer drug to be made available in Australia, New Zealand and South-East Asia.

Multi-omic data analytics collaboration between the University of Oxford and Holmusk.

NRGene’s genomic analysis project with Monsanto advances.

Samsung BioLogics receives first FDA approval at world’s largest plant.

TLC welcomes Mayor of Leiden and delegation to Taipei headquarter.

Warren Wang appointed senior vice president and president of Asia Pacific of Boston Scientific.

MiRXES reveals globalisation plans for 2018 and 2019.

QuintilesIMS is now IQVIA.

Quotient Sciences launches as the new global identity for Quotient Clinical.

ESMO Asia 2017 Congress.

More care is needed for cancer supportive care.

ALEX study shows alectinib 600 mg more effective than crizotinib in Asian lung cancer patients.

Study analyses mutations in cerebrospinal fluid in lung cancer with brain metastases.

Study finds all Myanmar mouth cancer patients chew betel quid.

In patients with idiopathic inflammatory myopathy, the presence of the melanoma differentiation-associated gene 5 (MDA5) antibody carries an extremely poor prognosis as a result of the associated interstitial lung disease (ILD) that is often rapidly progressive and refractory to therapies. Management of anti-MDA5 associated ILD is a challenging task as there is a paucity of clinical data and treatment guidelines in the literature. We hereby describe a proposed protocol for a multicenter randomized controlled trial to compare the efficacy of intravenous cyclophosphamide and obinutuzumab in combination with high-dose glucocorticoids and tacrolimus in terms of mortality at six months (primary outcome). The epidemiology, pathogenesis and treatment options of anti-MDA5 associated ILD are briefly reviewed.

Axial spondyloarthritis (SpA) is a spectrum of inflammatory conditions predominantly involving the spine and sacroiliac (SI) joints. The development of biological therapies has revolutionized the treatment paradigm in SpA. This has led to a great improvement in clinical outcomes, including inflammation suppression, symptom alleviation, and functional improvement. Despite its usefulness, the question regarding the optimal duration of therapy remains unanswered. This is particularly important given the cost associated with biological therapies, and the potential side effects related to immune suppression. Currently, guideline and data regarding dose reduction of biologics treatment in axial SpA has not been well established. This randomized controlled trial aims to study the possibility of biologic dose reduction in patients with axial SpA. The primary measure will be the occurrence of disease flare up in participants undergoing biologics tapering compared with participants on standard dose of treatment. The study also aims to evaluate the role of anti-drug antibodies in disease flare, the effect of biologics dose reduction on structural changes, and the cost effectiveness of biologics dose reduction. The results of this study will be crucial for clinical decisions and establishing future guidelines regarding dose reduction of biologics in SpA.